Loading
A phase 2 trial of Disitamab vedotin in non-small-cell lung cancer, ovarian cancer, endometrial cancer and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 is a phase 2 interventional study registered as NCT06003231 by Seagen, a wholly owned subsidiary of Pfizer, with 120 participants enrolled, started 2023-11-14 and due to reach its primary completion in 2026-03-27. Interventions recorded: disitamab vedotin.
Shares Disitamab vedotin, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, Pfizer (incl. Seagen), Endometrial cancer, Non-small-cell lung cancer and the tag pipeline.